Nolan Capital

Nolan Capital, Inc. is a family office based in Hermosa Beach, California, established in 2014. The firm specializes in private equity investments, focusing primarily on middle-market companies in various sectors, including consumer products and services, retail and restaurants, manufacturing, distribution, industrial products, business services, healthcare, and real estate. Nolan Capital typically targets companies in the United States that have an annual EBITDA ranging from $5 million to $20 million. The firm seeks to maintain long-term investments in its portfolio companies, aiming for substantial influence and growth within its chosen sectors.

Drew Dunnington

Vice President

Tim Eber

Associate

Wesley Knuth

COO

Paras Mehta Ph.D

Chief Investment Officer

Peter Nolan

Co-Founder and Chairman

Rob Weitz

Managing Director

8 past transactions

Palvella Therapeutics

Series D in 2023
Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Rocky Mountain Recreation Company

Acquisition in 2021
Rocky Mountain Recreation Company specializes in the management of recreational sites for federal, state, and local agencies. The company offers a comprehensive range of services, including the maintenance and management of campgrounds, marinas, and water recreation facilities. In addition to operational support, it provides amenities such as fast food services, fuel docks, boat rentals, and bait and tackle shops, along with the sale of various sundry items. By focusing on these services, Rocky Mountain Recreation Company aims to enhance the recreational potential of natural environments while ensuring their preservation and sustainability.

Jaguar Gene Therapy

Series B in 2021
Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

Taysha Gene Therapies

Series B in 2020
Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.

Encoded Therapeutics

Series D in 2020
Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

Palvella Therapeutics

Series C in 2020
Palvella Therapeutics is a biopharmaceutical company founded in 2015 and headquartered in Wayne, Pennsylvania. The company focuses on developing pathogenetically targeted therapies for serious and rare genetic skin diseases that lack approved treatments. Its lead candidate, QTORIN 3.9 % rapamycin anhydrous gel, is built on a patented QTORIN platform and is in late‑stage clinical development for two rare genodermatoses. Palvella’s approach emphasizes addressing the root cause of disease and delivering stable, room‑temperature formulations that penetrate the epidermis and dermis.

Taysha Gene Therapies

Seed Round in 2020
Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.